Literature DB >> 480851

[Radiotherapy of intraocular tumours, particularly of melanoma of the choroid (author's transl)].

P K Lommatzsch.   

Abstract

From 1964 to 1976 a number of 131 patients, suffering from melanoma of the choroid have been treated with 106Ru/106Rh beta-ray applicators. In 81 cases (61.8%) this treatment has been successful. 26 eyes (19.9%) had to be enucleated in spite of the irradiation. 24 patients (18.3%) died, 13 of them of metastases. Only in 46 patients, out of 81, we have reached total destruction of the tumor with flat chorioatrophic scar. In 27 cases visual acuity of 1.5 to 0.5 could be preserved. Radiogenic late complications in the capillary system with disturbances of the retinal blood circulation were the cause of visual deterioration. The 107 surviving patients were controlled during a period of 6.5 years in the average. Survival rate 91.2% after 5 and 84% after 10 years. Another group of 214 patients with melanoma of the choroid, who had been treated from 1955 to 1970 by enucleation reached a survival rate of 72% after 5 years. Treatment with 106Rh beta-irradiation therefore leads to no increased danger of metastases. The following indications for this treatment are suggested: 1. Prominence of the tumor not exceeding 5 mm, largest diameter at its base not more than 15 mm. 2. Distance of the dorsal edge of the tumor at least 1-2 optic disc diameters from the nerve head. 3. Peripheral delimitation against the ciliary body. 4. No tumor growth outside the eye.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 480851

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  9 in total

1.  Experimental study on the fractionation schedule for proton irradiation of uveal melanoma.

Authors:  G Wollensak; L Zografos; C Perret; E Egger; H Fritz-Niggli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

Review 2.  [Operative therapy and irradiation of conjunctival melanoma].

Authors:  H Westekemper; D Meller; R Darawsha; S L Scholz; D Flühs; K-P Steuhl; J Hérault; J Thariat; W Sauerwein
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

3.  18 years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma.

Authors:  R van Ginderdeuren; E van Limbergen; W Spileers
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

4.  [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].

Authors:  L M Heindl; M Lotter; V Strnad; R Sauer; G O H Naumann; H L J Knorr
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

5.  Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years' experience.

Authors:  P K Lommatzsch
Journal:  Br J Ophthalmol       Date:  1986-11       Impact factor: 4.638

6.  Primary choroidal and cutaneous melanomas, bilateral choroidal melanomas, and familial occurrence of melanomas.

Authors:  J A Oosterhuis; L N Went; H T Lynch
Journal:  Br J Ophthalmol       Date:  1982-04       Impact factor: 4.638

7.  Histopathologic findings in eyes treated with a ruthenium plaque for uveal melanoma.

Authors:  E Messmer; N Bornfeld; M Foerster; H Schilling; A Wessing
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

8.  Complications of local beta radiation of uveal melanomas.

Authors:  M H Foerster; N Bornfeld; U Schulz; A Wessing; G Meyer-Schwickerath
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

9.  Prognostic factors of choroidal melanoma in Slovenia, 1986-2008.

Authors:  Boris Jancar; Marjan Budihna; Brigita Drnovsek-Olup; Katrina Novak Andrejcic; Irena Brovet Zupancic; Dusica Pahor
Journal:  Radiol Oncol       Date:  2016-02-16       Impact factor: 2.991

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.